CompletedPhase 3NCT04110340
Ciprofloxacin Versus an Aminoglycoside Followed by Ciprofloxacin for Bubonic Plague
Studying Plague
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Oxford
- Principal Investigator
- Peter W Horby, MDUniversity of Oxford
- Intervention
- Ciprofloxacin(drug)
- Enrollment
- 222 target
- Eligibility
- All sexes
- Timeline
- 2020 – 2025
Study locations (1)
- Professor Mamy Randria, Antananarivo, Madagascar
Collaborators
Hôpital Universitaire Joseph Raseta Befelatanana CHU d'Antananarivo · Institut Pasteur de Madagascar · Foreign, Commonwealth and Development Office and Wellcome (216273.Z.19.Z)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04110340 on ClinicalTrials.govOther trials for Plague
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07207408Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of AgeDynavax Technologies Corporation
- RECRUITINGPHASE1NCT06943378Ph1, Randomized, Double-Blind and Controlled, Dose Escalation and Expansion Study to Assess the Safety and Pharmacokinetics of JST-010 in Healthy AdultsJust-Evotec Biologics
- RECRUITINGNANCT06083649The Dental Care Revolution: Health Education Using AI or Humanized Counseling on Plague Control and Periodontal Treatment Outcome in Patients With Periodontal DiseaseKaohsiung Medical University Chung-Ho Memorial Hospital